Explained Danielle Fishel Diagnosed with Stage Zero Cancer, What It Means

Updated Aug 21, 2024 | 05:00 PM IST

Explained: Danielle Fishel Diagnosed with Stage Zero Cancer, What It Means?

SummaryDanielle Fishel, known for "Boy Meets World," reveals stage-0 breast cancer diagnosis, emphasising the importance of regular screenings.

Danielle Fishel, the actress who played Topanga Lawrence in the popular 90s sitcom “Boy Meets World,” recently shared that she has been diagnosed with ductal carcinoma in situ (DCIS) or Stage 0 of breast cancer.

Fishel, 43, revealed the news on her podcast, “Pod Meets World,” which she co-hosts with her former co-stars Rider Strong and Will Friedle. During the episode, she explained that her cancer is classified as "stage zero," which means it was detected early and is typically easier to treat. She plans to undergo surgery to remove the cancerous cells, followed by additional treatment if necessary.

What is Stage 0 Cancer?

DCIS, or ductal carcinoma in situ, is a non-invasive form of breast cancer. In this condition, the cancer cells are located within the milk ducts of the breast but haven’t spread to nearby tissues. DCIS is considered a pre-invasive or stage zero cancer because it hasn’t yet become invasive, meaning it hasn’t spread beyond the ducts into other parts of the breast or body. The good news is that DCIS is highly treatable, and nearly all women diagnosed with it can be cured.

However, if left untreated, DCIS can progress to invasive breast cancer, which can spread to surrounding tissues and potentially other areas of the body. This is why early detection, like in Fishel’s case, is critical. By catching cancer at this early stage, treatment is more effective, and the prognosis is generally favorable.

Importance of Regular Screening

Fishel credited her regular breast cancer screenings for the early detection of her condition. She emphasized the importance of not delaying annual mammograms, sharing that her own early diagnosis was the result of promptly scheduling her screening after receiving a reminder.

Health experts agree that regular breast cancer screening is vital for early detection and better outcomes. Women of average risk are typically advised to start annual mammograms at age 40. However, those with a higher risk, such as a strong family history of breast or ovarian cancer, certain genetic mutations, or a history of certain benign breast conditions, may need to begin screening earlier.

Dr. Richard Reitherman, a radiologist and medical director of breast imaging at MemorialCare Breast Center, told Healthline that breast cancer risk increases with age, especially after 35. Women with a family history of breast cancer should talk to their doctors about starting screening earlier, possibly at an age 10 years younger than when their youngest affected family member was diagnosed.

End of Article
Novavax Says FDA Approval Back on Track for Its COVID Vaccine

Credits: Canva

Updated Apr 24, 2025 | 10:00 AM IST

Novavax Says FDA Approval Back on Track for Its COVID Vaccine

SummaryNovavax’s vaccine, which is the only protein-based COVID-19 vaccine, is awaiting for its full approval. Once approved, it could remain on the market even after the official end of the COVID-19 public health emergency.

Novovax, the maker of the only protein-based COVID-19 vaccine available in the US announced that its shot is on track for full approval from the US Food and Drug Administration (FDA). It is an important development for the company. It has sent its stock soaring up to 21% on Wednesday morning for trading. It is said that this will also ease the fears of political interference that may have caused delay in the process.

Vaccine For Emergency Use Only

While the other mRNA vaccines from Pfizer and Moderna have received full FDA approval for specific age groups, Novovax's vaccine still awaits the approval. It is only authorized for emergency use.

The emergency use authorization or the EUA allows vaccines to be distributed during public health emergencies. However, once the emergency ends, the FDA can remove them from the market unless full approval is granted.

Why Did The Delay Happen?

The FDA originally planned to approve Novovax's vaccine by April 1. However, as per the inside sources, the process was paused at the direction of Dr Sara Brenner, the FDA's acting commissioner. The delay has also raised concerns, especially after Dr Peter Marks, the FDA's longtime vaccine chief, reportedly left his post due to disagreements with the Health Secretary Robert F Kennedy Jr, who is a known vaccine skeptic.

What Makes Him A Vaccine Skeptic?

In the past, RFK Jr. has worked closely with many anti-vaccine activists who work for his nonprofit group Children's Health Defense. While in his recent speech, he said that he has "never been anti-vax and have never told the public to avoid vaccination", his track record shows otherwise.

In a podcast interview, he said, "There is no vaccine that is safe and effective" and told FOX News that he still believes in the now long-debunked idea that vaccines can cause autism. In another 2021 podcast, he urged people to "resist" CDC guidelines on getting their kids vaccinated. "I see somebody on a hiking trail carrying a little baby and I say to him, better not get them vaccinated," he said.

His non-profit also led an anti-vax campaign sticker and he appeared next on the screen to a sticker that read: "If you are not an anti-vaxxer you are not paying attention," reports AP.

What Does The Vaccine Need For Approval?

The FDA recently asked Novavax to outline a plan to collect additional clinical data from people who have received the vaccine. Novavax says it is “engaging with the FDA expeditiously” and hopes to secure full approval as soon as possible. Full FDA approval is considered the gold standard, as it reflects a higher level of scrutiny and confidence in a product’s safety and effectiveness.

How Is This Vaccine Different From Others?

The COVID-19 vaccines that are currently available in the US teach the immune system to recognize the virus' spike protein, which is its outer coating. the Pfizer and Moderna's mRNA vaccine deliver genetic instructions that help the body create a temporary version of spike protein that trigger an immune response. In contrast, the Novovax's shot contains lab-grown copies of the spike protein itself, which are then combined with a substance that boosts the immune response.

This traditional approach—called a protein-based vaccine—has been used for decades in vaccines for diseases like hepatitis B and shingles. For people who are hesitant about mRNA vaccines, Novavax offers an alternative that uses a well-established method.

End of Article
FDA Approves Dupixent for Chronic Spontaneous Urticaria in Adolescents and Adults

Credits: Canva

Updated Apr 24, 2025 | 07:00 AM IST

FDA Approves Dupixent For Chronic Spontaneous Urticaria In Adolescents And Adults

SummaryThe FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, offering improved symptom control and relief.

The US Food and Drug Administration (FDA) has granted approval to Dupixent or dupilumab for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents who are aged 12 years or are older. The approval caters to those who would have to continue to experience symptoms despite being on histmamine-1 (H1) antihistamine therapy. These are medications that block the effects of histamine on H1 receptors and are primarily used to treat allergies or allergic reactions.

What is Dupixent?

It is a biologic medication which targets specific pathways in the immune system. It is a monoclonal antibody, which is designed to inhibit the signaling of two key proteins, namely: interleukin-4 (IL-4) and interleukin-13 (IL-13). These two play a central role in type 2 inflammation, which is believed to contribute to a variety of allergic and inflammatory conditions. It is also approved for other conditions like atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

What is Chronic Spontaneous Urticaria?

As per the 2017 study published in Canadian Medical Association Journal, titled Chronic spontaneous urticaria, the condition is defined by the presence of hives daily or almost for at lease six weeks. The study also mentions that the condition mostly affects the working population and may have a substantial impact on quality of life.

As per the American College of Allergy, Asthma & Immunology, it affects about 20% of people at some time during their lives. It can also be triggered by many substances or situations and usually starts as an itchy patch of skin that turns into swollen red welts.

Rarely, cases of hives last more than six weeks and could end up staying for up to 5 years. This condition is known as chronic spontaneous urticaria or idiopathic urticaria. It can affect 1.4% of the general population and is seen in women twice as commonly as men.

For many individuals, the condition is both physically uncomfortable and emotionally distressing, often interfering with sleep, daily activities, and overall quality of life. In some patients, standard antihistamines fail to control the symptoms, leaving them in need of more effective treatment options.

How Was Dupixent Approved?

The FDA has based its decision on the results of two phase 3 clinical trials that studied the drug ass an add-on to the standard antihistamine therapy. The trials also included patients who had not previously been treated with biologic therapies and who continued to show symptoms despite being on antihistamines.

In both studies, Dupixent met its primary and key secondary endpoints. Patients receiving the medication showed a significant reduction in the severity of itching and urticaria activity after 24 weeks, compared to those who received placebo plus antihistamines. Additionally, those on Dupixent were more likely to achieve well-controlled disease or a complete response by the end of the study period. The safety profile observed in these trials was consistent with what has already been documented in other approved uses of Dupixent.

The approval of Dupixent for CSU represents a significant advancement for patients and healthcare providers. It offers new hope for those who have been living with poorly controlled symptoms, enhancing their ability to manage the condition more effectively and improve overall quality of life.

End of Article
Scientist Reveal New Optical Sensor Can Spot High Cholesterol And Predict Disease Risk Instantly

Updated Apr 23, 2025 | 11:00 PM IST

Scientist Reveal New Optical Sensor Can Spot High Cholesterol And Predict Disease Risk Instantly

SummaryCholesterol levels can silently elevate disease risks. Regular testing helps detect LDL buildup early, enabling timely lifestyle changes or medication to prevent heart attacks, stroke, or other serious health complications.

A future where heart attacks, strokes, and even cancer might be predictable is coming near—not only cured—thanks to a small, new eco-friendly sensor that can detect harmful levels of cholesterol in real-time. Scientists in India have created a revolutionizing optical sensor that can immediately identify high cholesterol, which could change the way we check for heart disease around the world.

At the core of this innovation is a unique biosensing platform that's not just extremely sensitive and affordable but also eco-friendly. Created by scientists at the Institute of Advanced Study in Science and Technology (IASST), Guwahati, in India this next-generation optical sensing tool is constructed using silk fiber functionalized with phosphorene quantum dots. Their work, reported in the highly regarded Nanoscale journal by the Royal Society of Chemistry, breaks new ground for non-invasive, real-time disease monitoring.

Why Early Detection of Cholesterol is Important to Overall Health?

Elevated cholesterol levels, particularly high LDL (low-density lipoprotein) or "bad" cholesterol, are frequently associated with silent but lethal diseases such as atherosclerosis, myocardial infarction, hypertension, venous thrombosis, and even some cancers. But the greatest concern? Most individuals never realize they're at risk until it's too late.

Cholesterol serves a double function in human physiology. It is required for the manufacture of vitamin D, bile acids, and steroid hormones and for the preservation of blood and nerve cell integrity. But too much—especially increased LDL (low-density lipoprotein, or "bad") and decreased HDL (high-density lipoprotein, or "good") cholesterol—can cause arteries to become clogged with plaque, blocking the flow of blood and causing life-threatening events.

That's why it is essential to detect these issues early on. And this new optical sensor might prove a breakthrough in the global battle against chronic illnesses by detecting risk signs before symptoms develop.

What makes this device a scientific milestone is the integration of materials and techniques that are innovative and environmentally friendly. The scientists employed silk fiber as the substrate and functionalized it with phosphorene quantum dots, which are renowned for their superior electrical and optical properties.

The sensor was also incorporated into a cellulose nitrate membrane to create an electrical sensing platform that can detect trace amounts of cholesterol—even below the normal detection limit. That's correct: this device can detect cholesterol changes before they reach clinical levels, making it perfect for regular health monitoring and preventive medicine.

This device produces no electronic waste, providing a green alternative to traditional diagnostic technologies.

How Does the Device Works?

In contrast to most experimental laboratory creations that fail to translate to real-world use, this device is highly compatible with real biological samples. It was able to detect cholesterol levels in human blood serum, rat blood, and even milk—showing its strength and versatility across mediums.

Such reliability makes it extremely versatile for application in point-of-care (POC) environments, possibly in clinics, pharmacies, or even at home. That translates to no more complicated lab tests or weeks of waiting for results.

One of the main causes of abnormal cholesterol is familial hypercholesterolemia, a genetic condition in which the liver has difficulty breaking down cholesterol. This makes regular checks even more crucial, particularly for those with a family history of heart disease, says the British Heart Foundation.

Obesity, inflammation, smoking, alcohol consumption, and sedentary lifestyles all increase LDL levels while simultaneously reducing protective HDL cholesterol. In many cases, the symptoms remain invisible—making it a ticking time bomb inside the body.

Visible signs such as deposits of fat beneath the skin (xanthomas), yellowish spots on or near the eyelids (xanthelasmas), or white circles around the iris (corneal arcus) may appear in rare cases. But for many individuals, high cholesterol has no warning signals.

Can Lifestyle Changes Replace Statins?

Though statins, drugs that inhibit the liver production of cholesterol—are common and have been shown to be effective, they're not the only solution. Lifestyle modification continues to be the cornerstone. Physicians suggest:

Physical activity on a daily basis: A minimum of 30 minutes to increase HDL and decrease LDL.

Changes in diet: Increased fiber, reduced saturated fats, and decreased processed foods.

Smoking and alcohol avoidance: Both are bad habits that make LDL worse and are detrimental to heart health.

The objective isn't merely treatment but prevention, and that is where early diagnosis using devices like this optical sensor comes into play.

This emerging optical sensor, capable of detecting cholesterol, is more than an academic achievement—it's a sea change. It signals a new world where your health is cared for proactively, sustainably, and customarily. Beyond its current ability to be handheld, this equipment may be designed into wearable devices, home health test kits, or even phones that are smarter with health attachments.

End of Article